[From a consensus conference to AMM (authorization to market): succinylcholine as an example].
Plaud
B
B
Debaene
B
B
D000075202:Contraindications; D017277:Drug Approval; D005602:France; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects / Q000191:economics; D013390:Succinylcholine / Q000009:adverse effects / Q000191:economics
D009467:Neuromuscular Depolarizing Agents; D013390:Succinylcholine